China’s Neushen Therapeutics, a biotech developer focused on central nervous system (CNS) disorders, has raised USD 20m in pre-Series A funding led by local VC firm Lapam Capital.
CNS disorders are increasingly recognized as major causes of death and disability worldwide while the diagnosis and treatments have largely lagged. Urgent measures are needed to tackle the growing challenges,...
India’s Innoven Capital, a joint venture between UOB and Temasek Holdings-owned Seviora Holdings, has fractionalised a USD 50m venture debt fund using blockchain and smart contracts.
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Temasek Holdings, A91 Partners, and Kae Capital have invested USD 135m in Indian omnichannel wellness products retailer HealthKart.